Bifidobacterium infantis 35624: The IBS Strain with Gold-Standard Data

Most probiotic claims are vague and strain-agnostic. Bifidobacterium infantis 35624 (now reclassified as Bifidobacterium longum subsp. longum 35624, sold as Align in the US) is an exception — its IBS evidence is strain-specific, placebo-controlled, and published in tier-1 gastroenterology journals.

The Whorwell Trial

The pivotal Whorwell 2006 dose-finding RCT in the American Journal of Gastroenterology (PMID 16863564; DOI 10.1111/j.1572-0241.2006.00734.x) compared three doses of B. infantis 35624 to placebo over 4 weeks in 362 women with IBS. The 1 × 10⁸ CFU/day dose produced statistically significant improvement in abdominal pain, bloating, bowel-habit dissatisfaction, and overall symptom relief. The lower (1 × 10⁶) and higher (1 × 10¹⁰) doses did not separate from placebo — a U-shaped dose response and a useful reminder that "more probiotic" is not always better.

The Cytokine Story

The O’Mahony 2005 trial in Gastroenterology (PMID 15765388; DOI 10.1053/j.gastro.2004.11.050) showed that B. infantis 35624 (but not the comparator Lactobacillus salivarius) normalised the pro-inflammatory IL-10 / IL-12 cytokine ratio in IBS patients alongside symptom relief — a plausible mechanism linking gut microbial composition, low-grade mucosal immune activation, and IBS symptoms. Few probiotic strains have this kind of mechanism-and-outcome alignment in the same patient population.

Dose and Product

The research dose for IBS is 1 × 10⁸ CFU/day of strain 35624. Commercial Align (Procter & Gamble) is the formulation that delivers this strain at this dose. Pharmacy-brand "Bifidobacterium infantis" products usually use unrelated strains that do not have the same data. If you are treating IBS, specify the 35624 strain on the label.

What to Expect

Onset of symptom improvement is typically 2–4 weeks of daily use. Across IBS as a class, the Ford 2014 meta-analysis in American Journal of Gastroenterology (PMID 25070051; DOI 10.1038/ajg.2014.202) found probiotics overall reduced the risk of persistent IBS symptoms (RR 0.79, 95% CI 0.70–0.89), but noted that which species and strain are most effective remains uncertain — B. infantis 35624 is one of the better-supported single strains within that average. Not all patients respond. If 8 weeks of consistent use shows no benefit, continuing is unlikely to help; switching to low-FODMAP, enteric-coated peppermint oil, or gut-directed psychological therapies is reasonable. Safety is excellent — mild bloating in the first few days is the most common adverse effect.